Eli Lilly published the results of its ATTAIN-1b trial for obesity in September 2025 7 , which compared orforglipron to placebo in more than 3,100 adults without diabetes, with a BMI of 30+ or 27-30 with an obesity-related complication including hypertension, dyslipidaemia, cardiovascular disease or obstructive sleep apnoea and a history of at least one patient-reported unsuccessful dietary effort to lose body weight, who have tried unsuccessfully to lose weight with diet alone
Side Effects The hallmarks of Depression, for which Prozac is prescribed, include a sad mood, loss of interest, weight gain or loss, fatigue, inappropriate guilt, difficulties concentrating, psychomotor agitation or retardation, and recurrent thoughts of death
Parties are expected to continue coordinated discovery and pretrial preparations while evaluating potential settlement outcomes
Compounded semaglutide and branded Wegovy share the same active molecule but differ in regulatory status, formulation, and sourcing
